Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$4.83 USD
+0.08 (1.68%)
Updated May 8, 2024 04:00 PM ET
After-Market: $4.82 -0.01 (-0.21%) 6:40 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Brokerage Reports
Puma Biotechnology, Inc. [PBYI]
Reports for Purchase
Showing records 1 - 20 ( 224 total )
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Alisertib Development Advancing; Disappointing 4Q23 Revenues: Lowering PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Initiation of ALISCA-Lung1 Phase 2 Trial of Alisertib Monotherapy in SCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Puma Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Nerlynx U.S. Sales Flat QoQ But Expected to Increase in 4Q23; Alisertib Phase 2 Trial to Initiate in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E